Solasia Pharma K.K. provided consolidated earnings guidance for the fiscal year ending December 31, 2021. For the period, the company expects revenue to be in the range of JPY 1,600 million to JPY 2,600 million, operating loss in the range of JPY 2,800 million to JPY 1,800 million, loss in the range of JPY 2,800 million to JPY 1,800 million and basic loss per share in the range of JPY 21.62 per share to JPY 13.90 per share.